» Articles » PMID: 19669199

HIV-1 Tat Mimetic of VEGF Correlates with Increased Microvessels Density in AIDS-related Diffuse Large B-cell and Burkitt Lymphomas

Overview
Journal J Hematop
Publisher Springer
Specialty Hematology
Date 2009 Aug 12
PMID 19669199
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Angiogenic switch marks the beginning of tumor's strategy to acquire independent blood supply. In some subtypes of non-Hodgkin's lymphomas, higher local vascular endothelial growth factor (VEGF) expression correlates with increased microvessel density. However, this local VEGF expression is higher only in tumors with elevated expression of the receptors of the growth factor, suggesting an autocrine growth-promoting feedback loop. Several studies have indicated that VEGF receptors are also targeted by Tat protein from the HIV-1-infected cells. Given the similarity of the basic region of Tat to the angiogenic factors (basic fibroblast growth factor, VEGF), Tat mimics these proteins and binds to their receptors. We evaluated the role of HIV-1 Tat in regulating the level of VEGF expression and microvessel density in the AIDS-related diffuse large B-cell (DLBCL) and Burkitt lymphomas (BL). By luciferase assay, we showed that VEGF promoter activity was downregulated in vitro in cells transfected with Tat. Reduced VEGF protein expression in primary HIV-1 positive BL and DLBCL, compared to the negative cases, supported the findings of promoter downregulation from the cell lines. Microvascular density assessed by CD34 expression was, however, higher in HIV-1 positive than in HIV-1 negative tumors. These results suggest that Tat has a wider angiogenic role, besides the regulation of VEGF expression. Thus, targeting Tat protein itself and stabilizing transient silencing of VEGF expression or use of monoclonal antibodies against their receptors in the AIDS-associated tumors will open a window for future explorable pathways in the management of angiogenic phenotypes in the AIDS-associated non-Hodgkin's lymphomas.

Citing Articles

HIV Promotes Neurocognitive Impairment by Damaging the Hippocampal Microvessels.

Sharma A, Wang H, Zhang Z, Millien G, Tyagi M, Hongpaisan J Mol Neurobiol. 2022; 59(8):4966-4986.

PMID: 35665894 PMC: 10071835. DOI: 10.1007/s12035-022-02890-8.


Elevated Cancer-Specific Mortality Among HIV-Infected Patients in the United States.

Coghill A, Shiels M, Suneja G, Engels E J Clin Oncol. 2015; 33(21):2376-83.

PMID: 26077242 PMC: 4500831. DOI: 10.1200/JCO.2014.59.5967.


The role of the tumor microenvironment in HIV-associated lymphomas.

Taylor J, Liapis K, Gribben J Biomark Med. 2015; 9(5):473-82.

PMID: 25985176 PMC: 4533913. DOI: 10.2217/bmm.15.13.


Role of neurotrophic factor alterations in the neurodegenerative process in HIV associated neurocognitive disorders.

Fields J, Dumaop W, Langford T, Rockenstein E, Masliah E J Neuroimmune Pharmacol. 2014; 9(2):102-16.

PMID: 24510686 PMC: 3973421. DOI: 10.1007/s11481-013-9520-2.


Cytokines and chemokines at the crossroads of neuroinflammation, neurodegeneration, and neuropathic pain.

Ramesh G, MacLean A, Philipp M Mediators Inflamm. 2013; 2013:480739.

PMID: 23997430 PMC: 3753746. DOI: 10.1155/2013/480739.


References
1.
Morini M, Benelli R, Giunciuglio D, Carlone S, Arena G, Noonan D . Kaposi's sarcoma cells of different etiologic origins respond to HIV-Tat through the Flk-1/KDR (VEGFR-2): relevance in AIDS-KS pathology. Biochem Biophys Res Commun. 2000; 273(1):267-71. DOI: 10.1006/bbrc.2000.2941. View

2.
Claudio P, Stiegler P, Howard C, Bellan C, Minimo C, Tosi G . RB2/p130 gene-enhanced expression down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in vivo. Cancer Res. 2001; 61(2):462-8. View

3.
Takahashi Y, Kitadai Y, Bucana C, Cleary K, Ellis L . Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res. 1995; 55(18):3964-8. View

4.
De Falco G, Bagella L, Claudio P, De Luca A, Fu Y, Calabretta B . Physical interaction between CDK9 and B-Myb results in suppression of B-Myb gene autoregulation. Oncogene. 2000; 19(3):373-9. DOI: 10.1038/sj.onc.1203305. View

5.
Waltenberger J . Modulation of growth factor action: implications for the treatment of cardiovascular diseases. Circulation. 1997; 96(11):4083-94. DOI: 10.1161/01.cir.96.11.4083. View